These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 19497744)
41. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652. Chong H; Yao X; Qiu Z; Qin B; Han R; Waltersperger S; Wang M; Cui S; He Y J Biol Chem; 2012 Jun; 287(24):20281-9. PubMed ID: 22511760 [TBL] [Abstract][Full Text] [Related]
42. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Liu S; Wu S; Jiang S Curr Pharm Des; 2007; 13(2):143-62. PubMed ID: 17269924 [TBL] [Abstract][Full Text] [Related]
43. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Naito T; Izumi K; Kodama E; Sakagami Y; Kajiwara K; Nishikawa H; Watanabe K; Sarafianos SG; Oishi S; Fujii N; Matsuoka M Antimicrob Agents Chemother; 2009 Mar; 53(3):1013-8. PubMed ID: 19114674 [TBL] [Abstract][Full Text] [Related]
44. Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide. Sánchez-Martín MJ; Urbán P; Pujol M; Haro I; Alsina MA; Busquets MA Chemphyschem; 2011 Oct; 12(15):2816-22. PubMed ID: 21905195 [TBL] [Abstract][Full Text] [Related]
45. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560 [TBL] [Abstract][Full Text] [Related]
47. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection. Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193 [TBL] [Abstract][Full Text] [Related]
48. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358 [TBL] [Abstract][Full Text] [Related]
49. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120. Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362 [TBL] [Abstract][Full Text] [Related]
50. Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides. Gomara MJ; Perez Y; Martinez JP; Barnadas-Rodriguez R; Schultz A; von Briesen H; Peralvarez-Marin A; Meyerhans A; Haro I Sci Rep; 2019 Mar; 9(1):3257. PubMed ID: 30824796 [TBL] [Abstract][Full Text] [Related]
51. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses. Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471 [TBL] [Abstract][Full Text] [Related]
52. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989 [TBL] [Abstract][Full Text] [Related]
53. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952 [TBL] [Abstract][Full Text] [Related]
55. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides. Tamamura H; Otaka A; Fujii N Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877 [TBL] [Abstract][Full Text] [Related]
56. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738 [TBL] [Abstract][Full Text] [Related]
57. Modular assembly of dimeric HIV fusion inhibitor peptides with enhanced antiviral potency. Xiao J; Tolbert TJ Bioorg Med Chem Lett; 2013 Nov; 23(22):6046-51. PubMed ID: 24094817 [TBL] [Abstract][Full Text] [Related]
58. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms. Platt EJ; Gomes MM; Kabat D J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426 [TBL] [Abstract][Full Text] [Related]
59. The M-T hook structure is critical for design of HIV-1 fusion inhibitors. Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603 [TBL] [Abstract][Full Text] [Related]
60. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41. Wang Y; Lu H; Zhu Q; Jiang S; Liao Y Bioorg Med Chem Lett; 2010 Jan; 20(1):189-92. PubMed ID: 19932616 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]